Empress Therapeutics CEO Jason Park explains his company’s approach to drug discovery and development as “bringing a genetic basis to small molecule drugs.” When the Cambridge, MA-based firm emerged from stealth last June with $50m in funding from Flagship Pioneering, Empress said it had already developed 15 drug leads from its Chemilogics platform that harnesses artificial intelligence and machine learning to model natural processes in the human body that might offer a guide to producing drugs.
Empress Looks To The Body’s Internal Chemistry For Drug Leads
Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.
More from Emerging Company Profiles
• By
Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.
• By
Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.
• By
Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.
• By
Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.
More from Start-Ups & SMEs
• By
The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.